Effects of Estrogen Deficiency on Energy Expenditure

NCT ID: NCT01846728

Last Updated: 2019-11-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Menopause is associated with weight gain, but the reasons why are not clear. In this study, the investigators will determine if reducing estrogen levels causes a decrease in the ability of the body to produce heat. If so, this would suggest this is one way that menopause may cause weight gain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this pilot study is to investigate the role of the female sex hormone estrogen, on metabolism, thermoregulation and energy expenditure. Weight and fat gain increase after the menopause, but reasons for this are not clear. Loss of estrogen may cause changes in how women regulate metabolism and thermoregulation, possibly leading to weight gain. Specifically, this study will determine how loss of estrogen affects facultative thermogenesis. Loosely defined, facultative thermogenesis represents heat production that is turned on when needed. For example, when body core temperature falls below a certain threshold, a shivering response is invoked in skeletal muscle to increase heat production and, thus, energy expenditure. However, exposure over several hours to mild cold temperatures that do not trigger shivering (16-20⁰ C) also induces an increase in energy expenditure (cold-induced non-shivering thermogenesis). Although several different tissues may contribute to this response, the recent identification of functional brown adipose tissue (BAT) in humans has promoted an interest in how BAT is activated in humans and its potential role in regulating energy balance and body weight. The investigators will measure BAT activity using PET/CT scans pre and post three months of estrogen suppression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Estrogen suppression

Estrogen production will be suppressed using Lupron, a drug that blocks normal production of ovarian hormones

Group Type EXPERIMENTAL

Estrogen suppression

Intervention Type DRUG

Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Estrogen suppression

Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lupron

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index \< 30 kg/m2
* Normal menstrual cycles
* Premenopausal

Exclusion Criteria

* irregular menstrual cycles defined as 2 or more missed cycles in the previous year
* on hormonal contraceptive or menopausal therapy
* positive pregnancy test
* intention to become pregnant or start hormonal contraceptive therapy during the period of study
* lactation
* severe osteopenia or osteoporosis (i.e., proximal femur or lumbar spine t scores \< -2.0)
* abnormal vaginal bleeding
* thyroid dysfunction
* uncontrolled hypertension
* exercising at least 30 minutes per day at a moderate to vigorous intensity \>1 d/wk) over the past 6 months
Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

Sponsor Role collaborator

University of Colorado, Denver

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Edward Melanson, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P50HD073063

Identifier Type: NIH

Identifier Source: secondary_id

View Link

13-0149

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Race on Gonadotropin Responses
NCT00455962 COMPLETED PHASE1/PHASE2
Estrogen, HDL, and Coronary Heart Disease in Women
NCT00083824 COMPLETED PHASE2/PHASE3
Progesterone and Resting Energy Expenditure
NCT04140968 TERMINATED PHASE4
Role of Menopause in Thermoregulation
NCT06798571 RECRUITING PHASE4